Celadon Pharmaceuticals PLC
LSE:CEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Everbridge Inc
F:2E7
|
US |
|
Yoshinoya Holdings Co Ltd
TSE:9861
|
JP |
|
Doosan Corp
KRX:000150
|
KR |
Celadon Pharmaceuticals PLC
EPS (Diluted)
Celadon Pharmaceuticals PLC
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
EPS (Diluted)
-£4
|
CAGR 3-Years
-251%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Croda International PLC
LSE:CRDA
|
EPS (Diluted)
£0
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Science in Sport PLC
LSE:SIS
|
EPS (Diluted)
£0
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Venture Life Group PLC
LSE:VLG
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Provexis PLC
LSE:PXS
|
EPS (Diluted)
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Akanda Corp
NASDAQ:AKAN
|
EPS (Diluted)
-$61
|
CAGR 3-Years
79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
See Also
What is Celadon Pharmaceuticals PLC's EPS (Diluted)?
EPS (Diluted)
-4.3
GBP
Based on the financial report for Dec 31, 2024, Celadon Pharmaceuticals PLC's EPS (Diluted) amounts to -4.3 GBP.
What is Celadon Pharmaceuticals PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-251%
Over the last year, the EPS (Diluted) growth was -124%. The average annual EPS (Diluted) growth rates for Celadon Pharmaceuticals PLC have been -251% over the past three years .
